ALX2004 vs BPI-361175

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

ALX2004

Developed by ALX Oncology Inc.

Phase 1 in Non-Small Cell Lung Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2027 · NCT07085091 (registry estimate)

No aligned efficacy figure on record for this race.

BPI-361175

Developed by Betta Pharmaceuticals Co.

Phase 1/2 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05329298 · Phase 1/2 · status unknown

This is an open-label, non-randomized phase 1/2 dose-escalation and expansion study in which every participant received BPI-361175 with no placebo or active comparator, and no blinding was used. Results have not been posted, and because the design never included a controlled comparison, it cannot demonstrate a controlled treatment effect regardless.

Next expected readout: January 2028 · NCT05393466 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointALX2004BPI-361175
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
Duration of response, median—Not reported—Not reported

PFS, median

ALX2004
—Not reported
BPI-361175
—Not reported

OS, median

ALX2004
—Not reported
BPI-361175
—Not reported

ORR

ALX2004
—Not reported
BPI-361175
—Not reported

Duration of response, median

ALX2004
—Not reported
BPI-361175
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ALX2004: no structured comparison results are available for Non-Small Cell Lung Cancer.

BPI-361175: no structured comparison results are available for Non-Small Cell Lung Cancer.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALX2004's landscape · BPI-361175's landscape